Corbus Pharmaceuticals (CRBP) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Intercure (INCR) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 50.6% versus a loss of 82.8%. Over five years, INCR leads with a -90.9% price change compared with -92.2% for CRBP. Corbus Pharmaceuticals is the larger company by market cap ($42.4 million vs $42.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | INCR |
|---|---|---|
| Share price | $2.06 | $3.24 |
| Market cap | $42.45M | $42.03M |
| 1-day change | -15.40% | -7.69% |
| YTD return | -74.69% | -28.79% |
| 1-year return | -82.85% | -50.57% |
| 5-year return | -92.23% | -90.87% |
| EPS (TTM) | $-6.04 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-78.54M | — |
| 52-week high | $12.88 | $7.55 |
| 52-week low | $2.01 | $3.12 |
| Distance from 52-week high | -84.01% | -57.09% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1551.94% | — |
| Average volume | 1.11M | 15.93K |
| Shares outstanding | 20.61M | 12.97M |
| Employees | 36 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCR has outperformed CRBP by 32.3 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
CRBP vs INCR FAQ
Which is bigger, Corbus Pharmaceuticals or Intercure?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $42.45M compared with $42.03M for Intercure (INCR).
Which stock has performed better over the past year, CRBP or INCR?
INCR returned -50.57% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Intercure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.